SCHEMBL897519

SCHEMBL897519

CC(C)[Si](C#Cc1cc2c(cc1N1CCN(C3CCC3)CC1)C(C)(C)c1[nH]c3cc(C#N)ccc3c1C2=O)(C(C)C)C(C)C

nearest known ligand 0.80

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
ALK Q9UM73 20/20 0.80
KDR P35968 4/20 0.72
KIT P10721 2/20 0.66

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24064314 0.91 ALK (0.75) ALKKDRKIT
SCHEMBL897000 0.90 ALK (0.86) ALKKDRKIT
SCHEMBL897067 0.89 ALK (1.00) ALKKDRKIT
SCHEMBL896881 0.88 ALK (1.00) ALKKDRKIT
SCHEMBL896822 0.87 ALK (0.80) ALKKDRKIT
SCHEMBL897186 0.86 ALK (0.84) ALKKDRKIT
SCHEMBL897965 0.85 ALK (0.83) ALKKDRKIT
SCHEMBL898011 0.85 ALK (0.82) ALKKDRKIT
SCHEMBL897316 0.85 ALK (0.82) ALKKDRKIT
SCHEMBL896869 0.85 ALK (1.00) ALKKDRKIT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250114327-A1 COMPOSITION COMPRISING TETRACYCLIC COMPOUND CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2025-04-10 US disclosed
US-20230398096-A1 COMPOSITION COMPRISING TETRACYCLIC COMPOUND CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2023-12-14 US disclosed
US-20230142119-A1 TETRACYCLIC COMPOUND CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2023-05-11 US disclosed
US-20220306578-A1 TETRACYCLIC COMPOUND CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2022-09-29 US disclosed
US-20210052550-A1 COMPOSITION COMPRISING TETRACYCLIC COMPOUND CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2021-02-25 US disclosed
EP-3698788-A1 COMPOSITION COMPRISING TETRACYCLIC COMPOUND CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2020-08-26 EP disclosed
US-10646468-B2 Composition comprising tetracyclic compound CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2020-05-12 US disclosed
EP-3613729-A1 TETRACYCLIC COMPOUNDS CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2020-02-26 EP disclosed
EP-2606886-B1 COMPOSITION COMPRISING TETRACYCLIC COMPOUND CHUGAI PHARMACEUTICAL CO LTD (JP) 2020-01-08 EP disclosed
EP-3345903-B1 TETRACYCLIC COMPOUNDS CHUGAI PHARMACEUTICAL CO LTD (JP) 2019-10-09 EP disclosed
US-20160340308-A1 TETRACYCLIC COMPOUND CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2016-11-24 US disclosed
US-20160317494-A1 COMPOSITION COMPRISING TETRACYCLIC COMPOUND CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2016-11-03 US disclosed
US-9440922-B2 Tetracyclic compound CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2016-09-13 US disclosed
EP-2441753-B1 TETRACYCLIC COMPOUND CHUGAI PHARMACEUTICAL CO LTD (JP) 2016-03-30 EP disclosed
EP-2975024-A1 TETRACYCLIC COMPOUNDS CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2016-01-20 EP disclosed
US-9126931-B2 Tetracyclic compound CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2015-09-08 US disclosed
US-20150150845-A1 TETRACYCLIC COMPOUND CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2015-06-04 US disclosed
EP-2606886-A1 COMPOSITION CONTAINING TETRACYCLIC COMPOUND Chugai Seiyaku Kabushiki Kaisha (JP) 2013-06-26 EP disclosed
EP-2441753-A1 TETRACYCLIC COMPOUND Chugai Seiyaku Kabushiki Kaisha (JP) 2012-04-18 EP disclosed
US-20120083488-A1 TETRACYCLIC COMPOUND CHUGAI SEIYAKU KABUSHIKI KAISHA 2012-04-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230142119-A1 TETRACYCLIC COMPOUND ALK, TTR, ACVR1 ALK 1/4885KDR 167/4885KIT 378/4885
US-20250114327-A1 COMPOSITION COMPRISING TETRACYCLIC COMPOUND ALK, ALPI, TTR ALK 1/4885KDR 71/4885KIT 250/4885
US-20120083488-A1 TETRACYCLIC COMPOUND ALK, TTR, ACVR1 ALK 1/4885KDR 167/4885KIT 378/4885
US-20220306578-A1 TETRACYCLIC COMPOUND ALK, TTR, ACVR1 ALK 1/4885KDR 167/4885KIT 378/4885
US-20230398096-A1 COMPOSITION COMPRISING TETRACYCLIC COMPOUND ALK, ALPI, TTR ALK 1/4885KDR 71/4885KIT 250/4885
US-20160340308-A1 TETRACYCLIC COMPOUND ALK, TTR, ACVR1 ALK 1/4885KDR 167/4885KIT 378/4885
US-20160317494-A1 COMPOSITION COMPRISING TETRACYCLIC COMPOUND ALK, ALPI, TTR ALK 1/4885KDR 71/4885KIT 250/4885
US-20210052550-A1 COMPOSITION COMPRISING TETRACYCLIC COMPOUND ALK, ALPI, TTR ALK 1/4885KDR 71/4885KIT 250/4885
US-20150150845-A1 TETRACYCLIC COMPOUND ALK, TTR, ACVR1 ALK 1/4885KDR 167/4885KIT 378/4885
US-10646468-B2 Composition comprising tetracyclic compound ALK, ALPI, TTR ALK 1/4885KDR 71/4885KIT 250/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.